Atossa Therapeutics, Inc.
Atossa Therapeutics develops medicines for unmet medical needs in oncology, focusing on breast cancer in women. Lead candidate (Z)-endoxifen is in Phase II trials to treat and prevent breast cancer. The company also works on immunotherapy/chimeric antigen receptor therapy programs. Founded in 2008, Atossa is headquartered in Seattle, Washington.
Overview
Strengths
- Price to book ratio (1.18) is lower than the sector mean (24.44).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- The company has high debt. Net Debt to EBITDA Ratio (2.36) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | - |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | - |